Background: It is generally assumed that the immune response by a host to the tumor depends on their antigenic differences. Whether quantitative aspects in this relationship play any role remains unclear.
Materials And Methods: Observation of tumor growth and regression in allogeneic murine models under various experimental conditions.
Results: Prior single inoculation with a tumor without take (apparently insufficient antigenic stimulation for the host) does not confer significant protection from subsequent challenges with the same tumor. Prior take and temporary growth of a tumor followed by regression (sufficient antigenic stimulation) confers absolute immunity to subsequent challenges by the same tumor. Mice with progressive allogeneic tumor growth (sufficient antigenic stimulation), following tumor resection develop absolute immunity to subsequent challenges with the same tumor. Prior immunization with irradiated tumor cells (10(4) - 10(6) SC weekly x 3, i.e. a sufficient antigenic stimulation) confers immunity to subsequent challenges with the same tumor, while immunization with 10(3) irradiated cells weekly x 3 (insufficient antigenic stimulation) does not confer immunity to subsequent challenges with the same tumor.
Conclusion: The spontaneous host response to an implanted tumor with weak antigenic differences is usually weak and delayed due to insufficient antigenic stimulation initially of the host, who is perfectly capable in dealing effectively with the same challenges when primed before by a temporary prior growth of this tumor or immunization with the same tumor.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
DNA Nanostructures-Based In Situ Cancer Vaccines: Mechanisms and Applications.
Small Methods
January 2025
Department of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, P. R. China.
Current tumor vaccines suffer from inadequate immune responsive due to the insufficient release of tumor antigens, low tumor infiltration, and immunosuppressive microenvironment. DNA nanostructures with their ability to precisely engineer, controlled release, biocompatibility, and the capability to augment the immunogenicity of tumor microenvironment, have gained significant attention for their potential to revolutionize vaccine designing. This review summarizes various applications of DNA nanostructures in the construction of in situ cancer vaccines, which can generate tumor-associated antigens directly from damaged tumors for cancer immune-stimulation.
View Article and Find Full Text PDFRecent advances in bacterial outer membrane vesicles: Effects on the immune system, mechanisms and their usage for tumor treatment.
J Pharm Anal
December 2024
Center for AIE Research, Shenzhen Key Laboratory of Polymer Science and Technology, Guangdong Research Center for Interfacial Engineering of Functional Materials, College of Materials Science and Engineering, Shenzhen University, Shenzhen, Guangdong, 518060, China.
Tumor treatment remains a significant medical challenge, with many traditional therapies causing notable side effects. Recent research has led to the development of immunotherapy, which offers numerous advantages. Bacteria inherently possess motility, allowing them to preferentially colonize tumors and modulate the tumor immune microenvironment, thus influencing the efficacy of immunotherapy.
View Article and Find Full Text PDFVirus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response.
Front Immunol
January 2025
School of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, China.
Virus-like particles (VLPs), as a unique form of nanocarrier, predominantly encompass hollow protein shells that exhibit analogous morphology and structure to naturally occurring viruses, yet devoid of genetic material. VLPs are considered safe, easily modifiable, and stable, making them suitable for preparation in various expression systems. They serve as precise biological instruments with broad applications in the field of medical biology.
View Article and Find Full Text PDFA novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.
Front Immunol
January 2025
Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Oncolytic vaccinia viruses (VVs) are potent stimulators of the immune system and induce immune-mediated tumor clearance and long-term surveillance against tumor recurrence. As such they are ideal treatment modalities for solid tumors including lung cancer. Here, we investigated the use of VVL-m12, a next-generation, genetically modified, interleukin-12 (IL-12)-armed VV, as a new therapeutic strategy to treat murine models of lung cancer and as a mechanism of increasing lung cancer sensitivity to antibody against programmed cell death protein 1 (α-PD1) therapy.
View Article and Find Full Text PDFMagnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels.
Front Immunol
January 2025
Adaptive Biotechnologies, Seattle, WA, United States.
Introduction: T cells are involved in the early identification and clearance of viral infections and also support the development of antibodies by B cells. This central role for T cells makes them a desirable target for assessing the immune response to SARS-CoV-2 infection.
Methods: Here, we combined two high-throughput immune profiling methods to create a quantitative picture of the T-cell response to SARS-CoV-2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!